AbbVie Inc. (ABBV)
|Net Income (ttm)||6.66B|
|Ex-Dividend Date||Oct 14, 2021|
|Day's Range||108.31 - 109.21|
|52-Week Range||75.49 - 120.07|
|Price Target||127.01 (+16.4%)|
|Est. Earnings Date||Oct 29, 2021|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, mar... [Read more...]
In 2020, AbbVie's revenue was $45.80 billion, an increase of 37.69% compared to the previous year's $33.27 billion. Earnings were $4.62 billion, a decrease of -41.44%.Financial Statements
According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 127.01, which is an increase of 16.37% from the latest price.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This gene-therapy specialist may need some help turning things around.
Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio b...
Three healthcare stocks that have momentum on their side and are good buys right now.
AbbVie (ABBV) closed the most recent trading day at $107.43, moving -1.74% from the previous trading session.
Blue-chip stocks that have growing cash flow, good value, and have strong growth are suitable investments as the market downturn worsens. The post 7 Blue Chips to Shield Your Portfolio From Market Downt...
I'm not yielding with these great dividend stocks.
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic A...
NORTH CHICAGO, Ill., Oct. 15, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approva...
They all pay more than double what you'll get with the average stock in the S&P 500.
In the latest trading session, AbbVie (ABBV) closed at $110.34, marking a -0.76% move from the previous day.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
IRVINE, Calif., Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breas...
AbbVie Inc (NYSE: ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential. Related: AbbVie Submits Upadacitinib Applicat...
A regulatory setback weighed on the drugmaker's shares last month.
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic...
NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiogr...
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondyl...
NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the e...
NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens.
AbbVie (ABBV) closed the most recent trading day at $108.73, moving -0.33% from the previous trading session.
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative colitis a...
There's a reason why there are so few of them in his portfolio.